Cancer is a Genetic Disease: Hereditary Cancer Syndromes and Genetic Testing
At a Glance
- Sample Required: Peripheral blood (3-5 mL) or saliva sample
- Fasting Rules: No fasting required
- Turnaround Time (TAT): 2-4 weeks
- Base Cost: [Insert Current 2026 Price]
Cancer is fundamentally a genetic disease—arising from alterations in DNA that disrupt normal cell growth and division. However, not all genetic changes are inherited. The majority of cancers are sporadic, caused by somatic mutations acquired during a person's lifetime. A smaller but significant fraction (5-10%) are hereditary, resulting from germline mutations passed down from parents. Understanding this distinction is critical for risk assessment, early detection, and targeted prevention.
Definition of Genetic Disease
A genetic disease is a health condition caused by a pathogenic variant in an individual's DNA. These variants can affect protein production or function, leading to a spectrum of clinical manifestations. Genetic diseases can be classified into:
- Single-gene disorders: Cystic fibrosis, sickle cell anemia, Huntington's disease.
- Chromosomal abnormalities: Down syndrome, Turner syndrome.
- Multifactorial conditions: Diabetes, heart disease, and many cancers—where multiple genes interact with environmental factors.
Cancer falls into the multifactorial category, but hereditary cancer syndromes are often caused by highly penetrant single-gene mutations.
The Genetic Basis of Cancer
Cancer arises from the accumulation of genetic and epigenetic alterations that confer a growth advantage to cells. Key gene classes include:
- Oncogenes: Promote cell division (e.g., HER2, EGFR).
- Tumor suppressor genes: Inhibit cell growth (e.g., TP53, BRCA1/2).
- DNA repair genes: Maintain genomic stability (e.g., MLH1, MSH2).
Somatic mutations occur in individual cells and are not inherited. Germline mutations are present in every cell and can be passed to offspring. Hereditary cancer syndromes are caused by germline mutations in genes like BRCA1/2, Lynch syndrome genes, and others.
Hereditary Cancer Syndromes
Hereditary cancer syndromes are characterized by an increased risk for specific cancer types, often at younger ages, and a family history that follows an autosomal dominant pattern. Common syndromes include:
| Syndrome | Associated Genes | Main Cancer Types | Inheritance |
|---|---|---|---|
| Hereditary Breast and Ovarian Cancer (HBOC) | BRCA1, BRCA2 | Breast, ovarian, prostate, pancreatic | Autosomal dominant |
| Lynch Syndrome | MLH1, MSH2, MSH6, PMS2, EPCAM | Colorectal, endometrial, ovarian, gastric | Autosomal dominant |
| Li-Fraumeni Syndrome | TP53 | Sarcomas, breast, brain, adrenal | Autosomal dominant |
| Familial Adenomatous Polyposis (FAP) | APC | Colorectal, duodenal, thyroid | Autosomal dominant |
Individuals with a family history of these cancers may benefit from genetic counseling and testing to clarify their risk.
When to Consider Genetic Testing
Genetic testing for hereditary cancer is recommended when:
- Multiple family members on the same side have the same or related cancers.
- Cancer diagnosed at an unusually young age (e.g., breast cancer before age 50).
- Multiple primary cancers in the same individual.
- Known pathogenic variant in the family.
- Specific ethnic backgrounds with higher mutation prevalence (e.g., Ashkenazi Jewish for BRCA).
Testing should always be preceded by genetic counseling to ensure informed decision-making.
Genetic Testing Methods: NGS and WES
At DNA Labs India, we utilize Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES) to analyze germline DNA for hereditary cancer risk. These technologies offer:
- High sensitivity: Detection of single nucleotide variants, insertions/deletions, and copy number changes.
- Multi-gene panels: Simultaneous analysis of 30-100+ cancer susceptibility genes.
- Cost-effectiveness: More affordable than sequential single-gene testing.
WES is particularly useful when a hereditary syndrome is suspected but the specific gene is unknown, or when the patient has a rare cancer type.
Interpreting Results
Results are classified according to ACMG guidelines:
- Positive: A pathogenic or likely pathogenic variant is identified, indicating increased cancer risk.
- Negative: No pathogenic variant found; risk may still be elevated based on family history.
- Variant of Uncertain Significance (VUS): A variant with unknown clinical impact; requires further family studies.
Genetic counseling is essential to explain results and guide management.
Risk Management and Prevention
For individuals with hereditary cancer mutations, enhanced surveillance and risk-reducing strategies can significantly improve outcomes:
- Increased frequency of imaging (e.g., MRI for breast cancer screening).
- Chemoprevention (e.g., tamoxifen for BRCA carriers).
- Risk-reducing surgeries (e.g., prophylactic mastectomy or oophorectomy).
- Lifestyle modifications to reduce overall cancer risk.
Early intervention can reduce cancer incidence and mortality.
Why Choose DNA Labs India?
DNA Labs India is an ISO 9001 certified laboratory committed to accurate and reliable genetic testing. Our team of medical geneticists and genetic counselors ensures comprehensive support from test selection to result interpretation. We follow strict quality control measures and adhere to ethical guidelines in genetic testing.